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Abstract
Glucagon regulates glucose homeostasis by controlling glycogenolysis and gluconeo-
genesis in the liver. Exaggerated and dysregulated glucagon secretion can exacerbate hy-
perglycemia contributing to type 2 diabetes (T2D). Thus, it is important to understand how
glucagon receptor (GCGR) activity and signaling is controlled in hepatocytes. To better un-
derstand this, we sought to identify proteins that interact with the GCGR to affect ligand-de-
pendent receptor activation. A Flag-tagged human GCGR was recombinantly expressed in
Chinese hamster ovary (CHO) cells, and GCGR complexes were isolated by affinity purifi-
cation (AP). Complexes were then analyzed by mass spectrometry (MS), and protein-
GCGR interactions were validated by co-immunoprecipitation (Co-IP) and Western blot.
This was followed by studies in primary hepatocytes to assess the effects of each interactor
on glucagon-dependent glucose production and intracellular cAMP accumulation, and then
in immortalized CHO and liver cell lines to further examine cell signaling. Thirty-three unique
interactors were identified from the AP-MS screening of GCGR expressing CHO cells in
both glucagon liganded and unliganded states. These studies revealed a particularly robust
interaction between GCGR and 5 proteins, further validated by Co-IP, Western blot and
qPCR. Overexpression of selected interactors in mouse hepatocytes indicated that two
interactors, LDLR and TMED2, significantly enhanced glucagon-stimulated glucose pro-
duction, while YWHAB inhibited glucose production. This was mirrored with glucagon-stim-
ulated cAMP production, with LDLR and TMED2 enhancing and YWHAB inhibiting cAMP
accumulation. To further link these interactors to glucose production, key gluconeogenic
genes were assessed. Both LDLR and TMED2 stimulated while YWHAB inhibited PEPCK
and G6Pase gene expression. In the present study, we have probed the GCGR interactome
and found three novel GCGR interactors that control glucagon-stimulated glucose produc-
tion by modulating cAMP accumulation and genes that control gluconeogenesis. These
interactors may be useful targets to control glucose homeostasis in T2D.
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OPEN ACCESS
Citation: Han J, Zhang M, Froese S, Dai FF,
Robitaille M, Bhattacharjee A, et al. (2015) The
Identification of Novel Protein-Protein Interactions in
Liver that Affect Glucagon Receptor Activity. PLoS
ONE 10(6): e0129226. doi:10.1371/journal.
pone.0129226
Academic Editor: Eric Xu, Van Andel Research
Institute, UNITED STATES
Received: February 10, 2015
Accepted: May 6, 2015
Published: June 15, 2015
Copyright: © 2015 Han et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by the Canadian
Institutes of Health Research (MOP-102588 and
MOP-324754), the Novo Nordisk Diabetes Innovation
Award, Natural Science and Engineering Research
Council (RGPIN-2015-05286) and the Shanghai Jiao
Tong University Wuxi Research Institute Operating
Grant (2011JDZX021). The funder had no role in
study design, data collection and analysis, decision to
publish and preparation of the manuscript.
Introduction
Glucagon, released from pancreatic islet alpha cells, promotes glycogenolysis and gluconeogene-
sis in the liver to elevate blood glucose levels during fasting. This effect is mediated via its cognate
receptor, GCGR. As a member of the class B G protein coupled receptor (GPCR) family, GCGR
acts primarily through Gs (PKA-cAMP pathway) but also through Gq, involving phospholipase
C (PLC) [1]. Upon receptor activation by glucagon, Gs alpha is released to activate adenylate cy-
clase and increase intracellular cAMP levels, subsequently activating protein kinase A (PKA) [2].
In addition, the stimulation of Gq leads to the activation of PLC, and the subsequent release of in-
tracellular calcium [3, 4]. As a hormone released in response to hypoglycemia, glucagon is critical
in maintaining glucose homeostasis. Elevated glucagon secretion and GCGR activity was ob-
served in diabetes patients [5]. Additionally, disruption of glucagon activity was shown to im-
prove hyperglycemia in ob/ob mice [6]. Therefore antagonists towards the GCGR are considered
to be a potential strategy to treat diabetes leading to the development of a number of GCGR an-
tagonists [7, 8]. The first GCGR antagonist identified was the small molecule skyrin, a fungal
bisanthroquinone, which was found to inhibit glucagon-stimulated cAMP formation and glucose
output from rat and human hepatocytes [9].Later, another GCGR antagonist, Cpd-A, was shown
in preclinical models to lower blood glucose, but circulating glucagon and glucagon-like peptide
1 (GLP-1) levels were moderately elevated [10]. Thus, the movement of these compounds to clin-
ical trials was limited by their relatively poor potency/specificity. To facilitate the discovery of
novel GCGR antagonists there is a need for a comprehensive understanding of factors/proteins
involved in the regulation of its activity and cell signaling.
Over the past decade, GPCR accessory proteins have received significant attention in an ef-
fort to explain the diverse functions of the receptors, such as KCTDs to the GABAB receptor
[11] and beta-arrestin 1 to the GLP-1 receptor [12]. Although the discovery of novel accessory
proteins for other GPCRs is unfolding, the interactome (interacting protein network) of GCGR
has yet to be reported. Daulat et al. were the first group to apply an affinity purification and
mass spectrometry (AP-MS) approach to reveal the interactome of a GPCR: melatonin recep-
tor 1 and 2 [13]. In addition, several studies have employed AP-MS to identify interactors of
both cytosolic and membrane bound proteins [14–16]. We recently identified a set of novel
GLP-1R interactors in CHO and MIN6 β cells expressing GLP-1R using a similar AP-MS
method which revealed 99 potential interactors [17]. Following validation, one of these novel
GLP-1R interactors, PGRMC1, was shown to significantly enhance GLP-1 stimulated insulin
secretion [17]. In the present study, we have employed an AP-MS screening approach to identi-
fy a GCGR interactome. This method allowed us to study the GCGR in both its unliganded
(quiescent) and liganded (activated) states, in mammalian cells.
Methods
Animals and cell culture
Mice of C57BL/6 background were used for experiments at ages of 8–12 weeks. Experiments
were approved by the Animal Care Committee (University of Toronto) and animals were han-
dled according to the Canadian Council of Animal Care guidelines. Stable human GCGR ex-
pressing human liver carcinoma (HepG2-GCGR) cells generated for this study were cultured
with high glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin, as were Chinese hamster ovary (CHO) cells.
Cells were passaged every 3–5 days. Transient transfections in HepG2-GCGR and CHO cells
were performed using Lipofectamine 2000 following the manufacturer’s protocol (Invitrogen,
Carlsbad, California).
Glucagon Receptor Interactors
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Isolated mouse hepatocytes
Mice (C57BL/6) aged 8–12 weeks were fasted overnight and primary hepatocytes were isolated
and cultured as previously described [18]. Briefly, primary hepatocytes were isolated using col-
lagenase IV (Sigma, Canada) perfusion. Cells were seeded using DMEM supplemented with 1
g/L glucose, 10 M/L sodium lactate, 0.01 μM/L dexamethasone, 5 mM/L HEPES, and 2 mM/L
L-Glutamine. Transient transfections were performed using Lipofectamine 2000 following the
manufacturer’s protocol.
Affinity precipitation and LC-MS/MS (AP-MS)
Fig 1A schematically outlines the approach used to screen for potential GCGR interacting pro-
teins. Proteins from non-transfected (NT) CHO cells and GCGR-Flag transfected CHO cells
with or without glucagon treatment (10 nM) were collected using lysis buffer (10% glycerol, 50
mM/L HEPES (pH 7.4), 150 mM/L NaCl, 2 mM/L EDTA, 0.25% DDM (n-Dodecyl-β-D-mal-
toside) supplemented with protease inhibitor cocktail (Roche,Basel, Switzerland). Anti-Flag
M2 affinity gel (Sigma-Aldrich, Canada) was used to precipitate the GCGR/interactor complex.
Anti-Flag M2 beads were washed three times with lysis buffer followed by three washes with 50
mM/L ammonium bicarbonate (pH 8.0). Protein complexes were eluted by 500 mM/L ammo-
nium hydroxide (pH 11.0), and then lyophilized for digestion using sequence grade trypsin
(Promega, PR-V5111).
The tryptic mixture was then injected for LC-MS/MS analysis (LTQ-XL) according to the
procedure reported previously [19]. Briefly, reverse phase (RP) analytical columns were made
of 14–19 cm of RP material (Jupiter 4 mm Proteo 90A; Phenomenex, Inc.). Peptides were elut-
ed by a 2 hour gradient method in which aqueous buffer A is progressively mixed with higher
proportions of organic buffer B (5% water, 95% acetonitrile and 0.1% formic acid) in RP col-
umns by the HPLC with a flow-rate of 20–50 nL/min. Peptide ions were dynamically selected
for fragmentation using data-dependent acquisition by the operating software (the five most
intense precursor ions of each MS scan were selected for subsequent tandem mass spectrome-
try [MS/MS]). The resulting peptide identifications returned by SEQUEST were filtered and as-
sembled into protein identifications using the transproteomic pipeline software running on a
Sorcerer platform (SageNResearch). Mascot was searched with a fragment ion mass tolerance
of 0.6 Da and a parent ion tolerance of 3.0 Da. Mascot (matrix Science) version 2.3.02 was used
for mouse or human database searching. We used the Prohits software (http://www.prohitsms.
com) to analyze the MS data and generate a comparative table regarding protein identification
information. We filtered the results using the following criteria/parameters: 1) “mascot
score> 50”, 2) “not nuclear, mitochondrial, cytoskeleton and heat shock proteins”, 3) “identi-
fied at least 2 times in 3 runs”.
Plasmids and regents
cDNA of human GCGR (c-terminal Flag-tagged) and GCGR interactors (c-terminal HA-
tagged) were constructed in pcDNA3.1. The purified plasmids were prepared using the Midi-
Prep kit (Qiagen, Toronto, Canada).
Western blot
For phosphorylation experiments, HepG2-GCGR cells were transfected with YWHAB and
allowed to recover for 48 hours. HepG2-GCGR cells were then pre-incubated in DMEM
supplemented with 0.5% fatty acid free BSA for 30 minutes. HepG2-GCGR cells were then
stimulated with 100 nM/L glucagon in DMEM supplemented with 0.5% fatty acid free BSA for
Glucagon Receptor Interactors
PLOS ONE | DOI:10.1371/journal.pone.0129226 June 15, 2015 3 / 19
Fig 1. Study design and protocol. A) Flow-chart of the AP-MSmethod for discovering novel GCGR interactors. CHO cells transfected with pcDNA3.1 were
used as a negative control. CHO cells transfected with GCGR-Flag were stimulated with 10 nM glucagon for 5 minutes. Each condition was repeated three
times. After protein extraction, anti-Flag Co-IP was conducted using M2 anti-Flag affinity gel, and affinity beads were then washed with wash buffer and
ammonium bicarbonate three times before elution by hydroxide (pH 11.0). Co-IP elutes were then used for in-solution trypsin digestion and HPLC-MS/MS
(LTQ-XL) to identify GCGR interacting proteins. B) GCGR-Flag is expressed in CHO cells transfected with human GCGR-Flag plasmid. Immunoprecipitation
was conducted using M2 anti-Flag affinity gel, 5% lysates (Input, I) and Co-IP elutes (E) loaded on 10% SDS-PAGE gel for electrophoresis. Flag M2
monoclonal antibody was used for Western blots. C) GCGR-Flag transfected CHO cells respond to glucagon stimulation through changes in cAMP levels.
EC50 = 0.41 nM. GCGR-Flag transfected CHO cells were used for glucagon stimulation (0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM) for 30 minutes for
the cAMP ELISA assay.
doi:10.1371/journal.pone.0129226.g001
Glucagon Receptor Interactors
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15 minutes. Total cell lysate was collected using the same lysis buffer used in affinity purifica-
tion with the addition of phosphatase inhibitors (10 mM/L sodium orthovanadate and sodium
fluoride). Anti-phosphoserine antibody (1:1000 dilution; Sigma-Aldrich, United States) and
HRP-conjugated mouse secondary antibody were used for detection of total serine phosphory-
lation. The membranes were developed with the ECL advance kit (GE Healthcare) and imaged
using the Kodak ImageStation4000 Pro (Care stream Health Inc, Rochester, New York).
Glucose production assay
Primary hepatocytes (2×105 cells per well in twelve-well plates) were first serum starved
overnight prior to stimulation. Following serum starving, primary hepatocytes were preincu-
bated with glucose-free DMEM without phenol red for 2 hours. Next, cells were washed with
PBS and stimulated with forskolin (10 μM/L), an adenylate cyclase activator, or glucagon
(100 nM/L) in glucose-free DMEM without phenol red for 4 h. The culture media were collect-
ed for measuring glucose concentration using the Glucose (GO) assay kit (Sigma, Canada).
The readings were then normalized to total protein content using the Bradford assay.
cAMP assay
Intracellular cAMP content was measured in primary hepatocytes as described previously [20].
Briefly, cells were washed with cold PBS and harvested using 80% ethanol. The cell lysates were
centrifuged and the supernatant was collected and lyophilized using a SpeedVac. The pellet
was resuspended in cAMP assay buffer (0.05 mM/L sodium acetate (pH 6.2) and 0.01% sodium
azide) and measured using an intracellular cAMP ELISA kit (Biomedical Technologies Inc,
US) in primary hepatocytes. In CHO and HepG2-GCGR cells, cAMP content was measured
using the Cisbio cAMP cell-based assay kit according to the manufacturer’s instructions [21].
Quantitative real-time PCR
Total RNA from primary hepatocytes was extracted using an RNA-easy kit (Qiagen, Canada).
cDNA generated by SuperScript II enzyme(Invitrogen, Canada) was analyzed by qPCR using
Power SYBR Green PCR master mix following the manufacturer’s protocol (Applied Biosys-
tems, Carlsbad, California) and Vii 7 Real-Time PCR System (Life-Technology, Canada). All
data was normalized to β-actin expression. Primers for PCR were designed using the Primer3
software program. Sequences for primers used for this study are provided in S1 Table. Relative
gene expression was estimated by the standard curve method [22].
GCGR binding assay
CHO cells seeded in 6-well plates were transiently co-transfected with Flag-tagged GCGR and
HA-tagged YWHAB or pcDNA3.1 and allowed to recover for 48 hours. Cells were then washed
twice in PBS and harvested using 2 mM/L EDTA in PBS. Cells (5x105/tube) were incubated at
37°C in binding buffer (DMEM, 1% BSA, pH 7.4) with I125 labeled glucagon using a range
from 10−12 to 10−6 M/L in a final volume of 200 μl. Cell suspensions were then centrifuged at
12,000 x g and radioactivity was counted using the Packard Cobra II Gamma Counter (GMI,
Ramsey, Minnesota, USA) [23].
Statistics and bioinformatics
The data are presented as the mean ± SE. Student’s t-test was used to measure the mean
difference for measurements of glucose production and cAMP in primary hepatocytes. One-
way ANOVA was used to measure the mean difference for cAMP production in CHO and
Glucagon Receptor Interactors
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HepG2-GCGR cells. Differences were considered statistically significant at p< 0.05. Cytoscape
(http://www.cytoscape.org) was used to generate a GCGR interactor network schematic [24].
We also conducted functional enrichment analysis for GCGR interactors using David Gene
Ontology tool (http://david.abcc.ncifcrf.gov). The p value (EASE Score, a modified Fisher
Exact p-Value) less than 0.05 means the input interactors’ list is specifically associated (en-
riched) in certain biological processes.
Results
Identification of GCGR interacting proteins using AP-MS
To study the GCGR interactome under liganded and unliganded states, CHO cells expressing
GCGR were treated with or without glucagon, followed by AP-MS analyses (Fig 1A). By West-
ern blot, we showed that the Flag-tagged GCGR was detected in total lysate and following affin-
ity purification using anti-Flag affinity gel (Fig 1B). Importantly, intracellular cAMP
accumulation was increased in response to incremental glucagon in GCGR overexpressing
CHO cells with the EC50 of 0.41 nM (Fig 1C), which is consistent with previous reports [25] in-
dicating the GCGR signaling pathway was properly integrated.
After AP-MS was performed in triplicate, 33 interactors were identified in both liganded
and unliganded states (Fig 2A), according to the criteria of 1) not identified in control group,
2) not nucleus, ribosome, cytoskeleton or heat shock proteins, 3) identified with at least one
unique peptide by MS/MS, and 4) identified at least twice. A complete list of the identified
GCGR interactors and their function can be found in S2 Table. Among these 33 interactors, 3
proteins (LDLR, GNB2 and TFR1) were only identified in the unliganded GCGR condition,
while 15 proteins (ATP1B3, VDAC1, ATNC10, S100A4, GAA, APH1A, YWHAB, S100A6,
NCSTN, YWHAE, TMED10, YWHAQ, MAT2A, GALK1, TMED2) were only found, as test-
ed, to bind to liganded GCGR. The remaining 15 proteins (RAB18, RAB11, ATP2B1, CAV1,
ADSS, SPTLC2, PGRMC1, ARF1, MMP14, NDRG1, ATP1A1, ATP2A2, RAB34, GNAi2,
VAPB) were identified in both the unliganded and liganded states (Fig 2A). By using the Uni-
prot protein database, we found that these putative interactors were largely associated with
three functional clusters; cellular signaling, molecular transport, and carbohydrate/lipid metab-
olism (Fig 2A).
Among 33 putative interacting proteins, only Gs alpha (i) was shown to be related to GCGR
function previously [1], while the remaining proteins have never been reported to interact with
GCGR. Interestingly, some of the proteins such as CAV1 and PGRMC1 were previously found
to interact with GLP-1R [17, 26]. We also performed functional enrichment analysis using the
David bioinformatics tool. Examining Gene Ontology biological processes, the 33 GCGR inter-
acting proteins were implicated functionally in protein localization (p = 0.0004), vesicle medi-
ated transport (p = 0.0012), intracellular signaling cascade (p = 0.0039), response to hormone
stimulus (p = 0.0074) and ion transport (p = 0.02) (Fig 2B).
Validation of the Interaction between GCGR and Identified Interactors
Based on the criteria of 1) membrane bound or cytosol proteins and 2) functional relevance to
receptors, we selected 8 interactors (LDLR, CAV1, YWHAQ, YWHAB, YWHAE, TMED2 and
TMED10, GALK1) and validated their interaction with GCGR by Co-IP and Western blot (Fig
3A).For each interacting protein, intensity of the elute/input band was quantified and express-
ed as an E:I ratio. The percentage of specific binding was calculated by subtracting the unspecif-
ic binding intensities from the control group [17]. The E:I ratio was used to estimate the
binding strength/percentage of interactors to GCGR (Fig 3B). Among the 8 proteins examined,
5 (CAV1, LDLR, TMED2, YWHAB, GALK1) were prominently detected in anti-Flag Co-IP
Glucagon Receptor Interactors
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Fig 2. A) The network of GCGR interactors and their functional clusters revealed by AP-MS. Biological functions were retrieved from the Uniprot
database. Each gray line indicates known protein-protein interactions extracted from the String database. Green nodes denote those interactors only
identified under unliganded state. Blue nodes represent exclusively liganded interactors. Yellow nodes are interactors that were found in both liganded and
unliganded states. B) Biological process enrichment analysis showed GCGR interactors are enriched with respect to specific biological functions, as
indicated by the DAVID bioinformatics tool. Shown here are biological processes that have an EASE Score <0.05 (a modified Fisher Exact p-Value).
doi:10.1371/journal.pone.0129226.g002
Glucagon Receptor Interactors
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Fig 3. Validation of novel GCGR interactors by Co-IP/WB in CHO cells.HA-tagged interactors and Flag-tagged GCGRwere co-transfected into CHO
cells, while cells only transfected with HA-tagged interactors were used as a control. Anti-Flag co-immunoprecipitation (Co-IP) and anti-HAWestern blot were
performed. A) Representative gels from the Co-IP/WB. I = Input proteins before Co-IP, W3 = 3rd wash, E = co-IP elutes. N = 3 per group. B) The relative
Glucagon Receptor Interactors
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elutes, suggesting their strong interaction with GCGR (Fig 3A and 3B). YWHAE was not de-
tected in the Co-IP elutes, and TMED10 and YWHAQ showed strong binding to anti-Flag af-
finity gel. These later 3 proteins did not pass the validation test and therefore were not selected
for functional studies.
Selected GCGR interactors affect glucose production in primary mouse
hepatocytes
GCGRs are expressed in selected tissues in the body but primarily in the liver. Activation of
GCGR by glucagon leads to increased glucose production in the liver, achieved by stimulating
both glycogenolysis and gluconeogenesis. To evaluate the effect of identified GCGR interactors
on GCGR function, we assessed glucose production in primary mouse hepatocytes. A green
fluorescent protein (GFP) plasmid was transfected into isolated mouse hepatocytes and the ex-
pression efficiency was confirmed to be upwards of 70% (Fig 4A). Glucose production in re-
sponse to glucagon was dose-dependent (Fig 4B), indicating proper GCGR signaling in these
cells. Five interactors validated by Co-IP andWestern blot were transfected into primary hepa-
tocytes. To examine glucose production in these primary hepatocytes, we used the EC50 con-
centration of 100 nM glucagon for treatment. We found that overexpression of CAV1 and
GALK1 increased glucose production at the basal (without glucagon treatment) concentration,
but not in the presence of glucagon (118.87±9.4%, p<0.05, N = 6 and 120.03±13.0%, p<0.05,
N = 6 respectively) (Fig 4C). More importantly, overexpression of two interactors (LDLR and
TMED2) enhanced glucagon-stimulated glucose production significantly (128.97±12.6%,
p<0.01, N = 6 and 131.15±10.3%, p<0.01, N = 6 respectively) but had no effect at the basal
level. Overexpression of another interactor, YWHAB, conversely reduced glucagon-induced
glucose production significantly (65.59±4.6%, p<0.01, N = 6) (Fig 4D) without affecting the
basal level glucose production in the primary hepatocytes. The fact that CAV1 and GALK1
only affected glucose production under basal conditions and not in the presence of glucagon,
suggested their effects may be independent of GCGR action. For this reason CAV1 and
GALK1 were excluded from further functional and mechanistic studies.
Assessment of cAMP accumulation mediated by selected GCGR
Interactors in primary mouse hepatocytes, CHO and HepG2 Cells
Upon glucagon binding, GCGR is activated to primarily trigger the cAMP-PKA pathway in
which increased cAMP accumulation activates PKA to ultimately elevate glucose production.
To determine whether GCGR interactors regulate the gluconeogenic process through the
cAMP pathway, we assessed the effect of overexpression of GCGR interactors on cAMP accu-
mulation in response to 0.1 nM glucagon treatment in primary hepatocytes (EC50 concentra-
tion of cAMP accumulation in response to glucagon, Fig 5A). As we anticipated,
overexpression of LDLR and TMED2 significantly increased glucagon induced cAMP accumu-
lation to127.74±2.1% (p<0.01, N = 6) and to 80.4±2.13% (p<0.05, N = 6) respectively. In con-
trast, overexpression of YWHAB significantly suppressed glucagon induced cAMP
accumulation by 57.24±7.9% (p<0.01, N = 6, Fig 5B). These findings are consistent with previ-
ous studies demonstrating that increased cAMP accumulation is the key factor of GCGR medi-
ated glucose production [1].
binding strength for each interactor. For each of the interacting proteins, intensity of the elute/input band was quantified and expressed as a ratio to the lysate
band (E:I ratio). The E:I ratio was used to estimate the percentage of input interactors binding to GCGR.
doi:10.1371/journal.pone.0129226.g003
Glucagon Receptor Interactors
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In line with this observation in primary mouse hepatocytes, in both CHO and HepG2 cells
expressing the glucagon receptor, YWHAB overexpression significantly decreased 0.1 nM
Fig 4. Effects of overexpression of selected GCGR interactors on glucose production in primary mouse hepatocytes. A) Transfection of GFP in
primary hepatocytes. B) Dose-response curve of glucagon induced glucose production in primary hepatocytes. 100 nM glucagon treatment significantly
increased glucose production in primary hepatocytes (**p<0.01). Readings were normalized to protein amount. Results are presented as mean ± S.E. of
three independent experiments. C) Overexpression of CAV1 and GALK1 increased glucose production significantly at basal level (*p< 0.05, **p<0.01 vs
cells transfected with pcDNA3.1); D) Overexpression of LDLR and TMED2 increased 100 nM glucagon-stimulated glucose production while YWHAB
decreased glucagon-stimulated glucose production significantly (*p< 0.05,**p<0.01 vs cells transfected with pcDNA3.1, N = 3 per group).
doi:10.1371/journal.pone.0129226.g004
Glucagon Receptor Interactors
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Fig 5. Effects of GCGR interactor overexpression on glucagon-induced cAMP accumulation in primary mouse hepatocytes, CHO cells expressing
GCGR and HepG2 stably expressing GCGR. A) Glucagon increased cAMP accumulation in primary mouse hepatocytes, CHO and HepG2-GCGR cells
(N = 3 per group) dose-dependently. Primary hepatocytes were transfected with selected GCGR interactors. B) 1 nM glucagon treatment increased cAMP
accumulation significantly (**p<0.01). Primary hepatocytes expressing LDLR and TMED2 increased glucagon induced cAMP response significantly
(**p<0.01 when compared to hepatocytes transfected with pcDNA3.1). Overexpression of YWHAB in hepatocytes decreased glucagon induced cAMP
accumulation (**p<0.01 when compared to hepatocytes transfected with pcDNA3.1).The results are shown as mean ± S.E. Each sample was analyzed in
Glucagon Receptor Interactors
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glucagon induced cAMP accumulation in both CHO and HepG2 cells expressing the glucagon
receptor (p<0.05, N = 3, Fig 5C and 5D). In CHO cells, overexpression of LDLR and TMED2
led to a significant increase in glucagon induced cAMP accumulation compared to control
(Fig 5C). Interestingly, no significant difference in cAMP accumulation was found in HepG2-
GCGR cells overexpressing LDLR and TMED2. Upon adenylate cyclase activation with forsko-
lin stimulation, YWHAB overexpression did not affect cAMP accumulation in CHO cells
expressing GCGR (Fig 5E), indicating the effect of YWHAB is mediated via molecules up-
stream of adenlyate cyclase, likely the GCGR, and that it is not a general inhibitor of adenylate
cyclase.
Gene expression of gluconeogenesis related genes in primary mouse
hepatocytes after overexpressing selected interactors
Gluconeogenesis is responsible for increased glucose production in the liver. It is up-regulated
by increased PKA-cAMP signaling/cAMP accumulation [27]. To further understand the
mechanism of action of the 3 interactor’s (LDLR, TMED2 and YWHAB) effects on glucose
production and GCGR signaling, we examined whether the expression of key gluconeogenic
genes were regulated in accordance with altered cAMP accumulation in primary hepatocytes.
Phosphoenolpyruvatecarboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) are critical
in gluconeogenesis and GCGR mediated glucose production [28]. PEPCK catalyzes the GTP-
dependent conversion of oxaloacetate to phosphoenolpyruvate and G6Pase catalyzes the
Mg2+-dependent hydrolysis of glucose-6-phosphate to glucose and inorganic phosphate. In
our current study, overexpression of LDLR, TMED2 or YWHAB had no effect on gene expres-
sion of these two enzymes at the basal level (Fig 6A and 6B). More importantly, glucagon in-
duced expression of PEPCK and G6Pase in LDLR overexpressing hepatocytes was significantly
increased to 76.52±2.3% and 108±1.7% respectively (p<0.01, N = 6) compared to the control
cells (Fig 6A and 6B). Similar to LDLR, TMED2 upregulated G6Pase gene expression signifi-
cantly to 114.15±3.5% (p<0.01, N = 6) in response to glucagon (Fig 6B). These findings sug-
gested that LDLR and TMED2 may be involved in up-regulation of gluconeogenesis in the
liver. Conversely, YWHAB overexpression significantly reduced glucagon-induced PEPCK
and G6Pase gene expression to 52.31±1.4% (p<0.05, N = 6) and 41.61±0.8% (p<0.01, N = 6)
respectively (Fig 6A and 6B).
YWHAB decreases cAMP production upon receptor activation prior to
adenylate cyclase activation
Because YWHAB was the interactor shown to decrease cAMP and glucose production, which
is of particular relevance to the treatment of T2D, we sought to further elucidate the mecha-
nism through which YWHAB achieved this observed attenuation. Based on the previously de-
scribed roles of YWHAB as an adaptor protein, we hypothesized that it may delay recycling of
GCGRs that have been phosphorylated and endocytosized from the cell membrane by blocking
action of phosphatases [29]. We used a binding assay to examine if YWHAB would change
GCGR binding affinity as well as the GCGR total binding (expression) on the cell membrane.
The IC50 in control cells did not differ from that of YWHAB overexpressing cells. Therefore,
triplicate. C) Overexpression of YWHAB significantly decreased glucagon-induced cAMP accumulation in CHO cells expressing GCGR (*p<0.05 when
compared to the pcDNA3.1 control group, N = 3); Overexpression of LDLR and TMED2 significantly increased glucagon-induced cAMP accumulation in
CHO cells expressing GCGR (*p<0.05, N = 3), 0.1 nM glucagon. D) Overexpression of LDLR, TMED2 had no significant effect on glucagon-induced cAMP
accumulation in HepG2-GCGR cells (p>0.05, N = 4). YWHAB overexpression decreased glucagon-induced cAMP accumulation (*p<0.05, N = 3), 0.1 nM
glucagon. E) Overexpression of YWHAB did not affect forskolin-induced cAMP accumulation in CHO cells expressing GCGR.
doi:10.1371/journal.pone.0129226.g005
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Fig 6. Effects of overexpression of GCGR interactors on expression of gluconeogenesis related genes. Primary hepatocytes were transfected with
selected interactors. After pre-incubation of serum-free DMEM, cells were treated with 100 nM glucagon for two hours. mRNA levels of
phosphoenolpyruvatecarboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were measured by qPCR. A) Overexpression of LDLR increased
glucagon-induced PEPCK gene expression in primary mouse hepatocytes (*p<0.05 vs hepatocytes transfected with pcDNA3.1, N = 3 per group). B)
Overexpression of LDLR and TMED2 increased glucagon induced G6Pase gene expression in primary mouse hepatocytes (**p<0.01 vs hepatocytes
transfected with pcDNA3.1, N = 3 per group). Data are expressed as means ± S.E, presented relative to β-actin transcript expression level.
doi:10.1371/journal.pone.0129226.g006
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YWHAB did not significantly change the binding affinity for glucagon (Fig 7A). It is notewor-
thy that the initial radioactive counts in the binding assay did not differ between these two
groups strongly suggesting that the amount of GCGR on the cell membrane was not markedly
changed (Fig 7B).
Fig 7. Assessment of the mechanism through which YWHAB decreases cAMP production. A) The affinity and B) radioactive counts of glucagon/
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On another aspect, we did not observe any change in serine phosphorylation in HepG2-
GCGR cells overexpressing YWHAB compared to control cells suggesting that YWHAB does
not alter total serine phosphorylation upon glucagon binding. (Fig 7C).
Discussion
Recently the crystal structure of GCGR, in particular its binding motif with glucagon, was re-
vealed [30] providing new insights into glucagon’s interaction with its receptor. However,
GCGR signaling is complex and the factors modulating its activity are not fully understood. In
the present study, by using AP-MS we revealed a set of novel interactor proteins of the human
GCGR. Three novel interactors (LDLR, TMED2 and YWHAB) were shown to regulate gluca-
gon stimulated glucose production in primary mouse hepatocytes.
Protein-protein interactions (PPIs) have been intensively explored to understand fine tun-
ing of receptor function and signaling in the cells. In recent years AP-MS is emerging as a use-
ful tool for studying PPIs and has been applied to cancer cell signaling and metabolic disease
[17, 21,31–32]. More importantly, it allows for the study of activated receptors in a mammalian
setting, complementary to our previous study of GLP-1R using the advanced membrane yeast-
2-hybrid system, MYTH [21]. Compared to MYTH, AP-MS targets the receptor interactor
complex including indirect interactions rather than direct protein-receptor interactions. These
features might provide a more comprehensive perspective of the receptor’s interactome in
comparison to other discovery tools. As a result of our study, we identified 33 interactors wide-
ly involved in cell signal transduction, and metabolism and transport, including two G protein
subunits (GNIA2 and GNB2) that are well known to bind to GCGR. Functional enrichment
analysis showed most of these GCGR interactors are related to vesicle mediated transport
and protein localization, which may be important for GCGR trafficking. Of the 8 interactors
(LDLR, CAV1, YWHAQ, YWHAB, YWHAE, TMED2 and TMED10, GALK) selected for vali-
dation by Co-IP andWestern blot, 3 were not detected in the eluate of GCGR-Flag affinity gel.
This could be explained by the possibility that the interaction was too weak to be detected, or
that the interaction was indirect. In our earlier study using a similar AP-MS strategy, we identi-
fied a set of GLP-1R interactors [17]. The native ligands of GLP-1R (GLP-1) and GCGR (gluca-
gon) are transcribed from the same gene and spliced from the same propeptide, proglucagon.
Since GLP-1R and GCGR are structurally related and belong to class B GPCR family, it is not a
surprising that the two receptors shared similar functional clusters of interacting proteins in-
cluding G proteins (i.e. GNAI2), cell signaling (i.e. YWHAQ and PGRMC1), and molecular
transport (i.e. CAV1 and TMED10). However, compared to GLP-1R, GCGR had a unique
functional group of interactors involved in lipid and carbohydrate metabolism (LDLR and
GALK1), in accordance with its unique role in regulating glucose homeostasis.
Further study of glucose production in primary mouse hepatocytes supported our previous
hypothesis that these cells possess interactors that regulate activated GCGR. Over expression of
3 GCGR interactors (LDLR, TMED2 and YWHAB) had significant effects on glucagon stimu-
lated glucose production (GSGP). Interestingly, overexpression of two liganded interactors
CAV1 (an interactor of both liganded and unliganded GCGR) and GALK enhanced basal glu-
cose production but had no effect on glucagon-stimulated glucose production in primary
mouse hepatocytes. It is possible that these two interactors require involvement of other factors
to regulate GCGR. On the other hand, we also found that unliganded GCGR interactor LDLR
had a significant effect on glucagon-stimulated glucose production. This could be due to its
profound and complex involvement in lipid metabolism, which also links with glucose produc-
tion. The reported major role of LDLR is to bind and internalize circulating cholesterol-con-
taining lipoprotein particles which is required for LDL catabolism [33]. Although increased
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hepatic VLDL is a characteristic of T2D [34], LDL levels remains normal. This is possibly due
to increased LDL catabolism in early T2D patients who are hyperinsulinemic [35]. Further
studies also suggested possible links between LDLR up-regulation and insulin signaling [36,
37]. Therefore in our experimental paradigm, although LDLR was identified as an interactor of
unliganded GCGR, elevated LDLR level may increase lipid metabolism which could in turn af-
fect glucose production. Interestingly, beta-arrestin 2 binds to LDLR and modulates LDLR en-
docytosis [38], and beta-arrestin 1 can interact with class B GPCR, for example GLP-1R and
gastric inhibitor peptide receptor (GIPR),to mediate their effects on Gs-cAMP signaling [12,
39]. Therefore, in our model, LDLR may interact with GCGR and regulate glucagon induced
cAMP signaling through beta-arrestin 1 in primary hepatocytes.
The interactor TMED2 is reported to be part of the coat protein complex (coatomer) [40]
and is important to vesicle transport by interacting with ADP-ribosylation factor 1 (ARF1)
[41–43]. Recently it was shown to play a role in trafficking of GPCRs, including protease-acti-
vated receptor-2 (PAR-2) and calcium sensing receptor (CaSR), from the ER/Golgi to the plas-
ma membrane [44]. These studies showed that TMED2 could decrease receptor degradation
and stabilize the receptor in the ER, possibly enhancing plasma membrane targeting. In partic-
ular, similar to our finding, TMED2 was identified in the yeast-two-hybrid screens with CaSR
C-terminus [44], suggesting it is an important partner of GPCRs. In the context of this study,
elevated levels of TMED2 upon glucagon stimulation might increase the trafficking of GCGR
from Golgi to plasma membrane thereby enhancing the glucagon/GCGR pathway. This as-
sumption is supported by increased cAMP accumulation and elevated expression of down-
stream gluconeogenesis related genes, supporting a positive role for TMED2 in the regulation
of GCGR activity in glucose production in the liver.
The interactor 14-3-3 protein beta, also known as tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, beta (YWHAB) belongs to the 14-3-3 protein family. By
bioinformatic analysis in a T2D mouse liver membrane proteome study, YWHAB was revealed
as a novel protein with correlations to a set of membrane proteins that were differentially ex-
pressed in T2D [45]. YWHAB regulates the activity of ChREBP (carbohydrate response ele-
ment-binding protein), which regulates expression of genes involved in hepatic glycolysis and
lipogenesis [46]. Furthermore, 14-3-3 protein zeta was shown to co-immunoprecipitate with
GSK3 and tau in the brain [47, 48] and it also facilitates GSK3-catalyzed tau phosphorylation
in HEK293 cells [49]. Although the role of GSK3 in glycogen synthesis is yet to be defined in
different tissues, it is reasonable to speculate in our scenario that it could be a downstream ef-
fector of YWHAB that reduces glucose production by the regulation of glycogen synthesis. Al-
though YWHAB was not reported to affect cAMP signaling, its overexpression caused
suppression of gluconeogenesis in mouse primary hepatocytes and decreased cAMP accumula-
tion (Figs 4D and 5A).
One possible mechanism through which YWHAB decreases cAMP may be through an in-
teraction between arrestins and GCGR. Upon binding of a ligand to a GPCR, desensitization of
the receptor begins immediately to limit the potential harmful effects of continual activation
[50]. This desensitization is the result of concerted action of GRKs, arrestins and other protein
kinases [50]. Phosphorylation of a stimulated receptor by GRKs leads to recruitment of arrest-
ins to physically uncouple the receptor from its associated G protein. Additionally, protein ki-
nases, such as PKA, also directly phosphorylate the receptor [50], as well as GRKs to increase
their activity [50]. Since YWHAB was shown to decrease cAMP production upon glucagon
stimulation without acting as a general inhibitor of cAMP production, and did not lead to any
decreases in ligand affinity nor in cell surface expression of GCGR, we predict that YWHAB
may play a role in mediating the interaction between arrestins and the GCGR. We did not ob-
serve any change in glucagon-stimulated total serine phosphorylation in cells overexpressing
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YWHAB, suggesting that GCGR phosphorylation is not regulated by YWHAB to affect activi-
ty. However, further examination of the specific serine phosphorylation status of GCGR is re-
quired to rule this out completely. Another potential mechanism through which YWHAB may
lead to a decrease in cAMP production is through a similar interaction between PKA and the
receptor, or a complex involving PKA, GRKs and the receptor.
Conclusions
In mammalian cells, using the full-length human GCGR as a probe, we revealed a complex
GCGR protein interactome. Selected GCGR interactors were shown to regulate glucagon-stim-
ulated glucose production by modulating glucagon-induced cAMP accumulation and gluco-
neogenesis. This correlated with specific changes in key gluconeogenic genes in mouse
hepatocytes. One interactor of interest, YWHAB, may be involved in GCGR desensitization,
attenuating glucagon-stimulated glucose production. These findings highlighted the feasibility
of employing the AP-MS/MS strategy to identify novel GPCR interactors. This study provides
further novel insight into GCGR signaling and identifies novel targets for the development of
anti-glucagon action agents.
Supporting Information
S1 Table. Primer sequences for qPCR.
(DOCX)
S2 Table. GCGR interactors identified from the AP/MS screen.
(DOCX)
Author Contributions
Conceived and designed the experiments: MBW SA LWWJ. Performed the experiments: JH
MZ SF AB XHMR. Analyzed the data: JH MZ SF MR. Contributed reagents/materials/analysis
tools: SA. Wrote the paper: JH SF FDMB LW.
References
1. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled re-
ceptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptor Channels. 2002, 8(3–4): 179–188.
2. Li XC, Carretero OA, Shao Y, Zhuo JL. Glucagon receptor-mediated extracellular signal-regulated ki-
nase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hyper-
tension. 2006, 47(3): 580–585. PMID: 16391176
3. XuY X Xie. Glucagon receptor mediates calcium signaling by coupling to G alpha q/11 and G alpha i/o
in HEK293 cells. J Recept Signal Transduct Res. 2009, 29(6): 318–325. doi: 10.3109/
10799890903295150 PMID: 19903011
4. Cho YM, Merchant CE, Kieffer TJ.Targeting the glucagon receptor family for diabetes and obesity ther-
apy. Pharmacol Ther. 2012, 135(3): 247–278. doi: 10.1016/j.pharmthera.2012.05.009 PMID:
22659620
5. Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.
Endocrinology. 2012, 153(3): 1039–1048. doi: 10.1210/en.2011-1499 PMID: 22166985
6. Salehi A, Vieira E, Gylfe E. Paradoxical stimulation of glucagon secretion by high glucose concentra-
tions. Diabetes. 2006, 55(8): 2318–2323. PMID: 16873696
7. Mu J, Qureshi SA, Brady EJ, Muise ES, Chandelore MR, Jiang G. Anti-diabetic efficacy and impact on
amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One.
2012, 7(11): e49572. doi: 10.1371/journal.pone.0049572 PMID: 23185367
8. GuW,Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q. Glucagon receptor antagonist-mediated
improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am J Phy-
siol Endocrinol Metab. 2010, 299(4): e624–632. doi: 10.1152/ajpendo.00102.2010 PMID: 20647556
Glucagon Receptor Interactors
PLOS ONE | DOI:10.1371/journal.pone.0129226 June 15, 2015 17 / 19
9. Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE. Effects of skyrin, a receptor-se-
lective glucagon antagonist, in rat and human hepatocytes. Diabetes. 2000, 49(12): 2079–2086.
PMID: 11118010
10. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, Woods J, et al. Chronic treatment with a glucagon recep-
tor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1
without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia. 2011, 54(9): 2381–
2391. doi: 10.1007/s00125-011-2217-2 PMID: 21695571
11. Schwenk J, Metz M, Zolles G, Turecek R, Fritzius T, Bildl W, et al. Native GABA(B) receptors are het-
eromultimers with a family of auxiliary subunits. Nature. 2010, 465(7295): 231–235. doi: 10.1038/
nature08964 PMID: 20400944
12. Sonoda N, Lmamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM. Beta-Arrestin-1 mediates glu-
cagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci
U S A. 2008, 105(18): 6614–6619. doi: 10.1073/pnas.0710402105 PMID: 18445652
13. Daulat AM, Maurice P, Froment C, Guillaume JL, Broussard C, Monsarrat B, et al. Purification and iden-
tification of G-protein coupled receptor protein complexes under native conditions. Molecular and Cellu-
lar Proteomics. 2007, 6(5): 835–844. PMID: 17215244
14. Ahmed SM, Daulat AM, Angers S. Tandem affinity purification and identification of heterotrimeric g pro-
tein-associated proteins. Methods Mol Biol. 2011, 756: 357–370. doi: 10.1007/978-1-61779-160-4_22
PMID: 21870239
15. Chen GI,Gingras AC. Affinity-purification mass spectrometry (AP-MS) of serine/threonine phospha-
tases. Methods, 2007, 42: 298–305. PMID: 17532517
16. Anastas JN, Biechele TL, Robitaille M, Muster J, Allison KH, Angers S, et al. A protein complex of
SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast can-
cer progression. Oncogene, 2012, 31: 3696–3708. doi: 10.1038/onc.2011.528 PMID: 22179838
17. Zhang M, Robitaille M, Showalter AD, Huang X, Liu Y, Bhattacharjee A, et al. Progesterone receptor
membrane component 1 is a functional part of the GLP-1 receptor complex in pancreatic beta cells. Mo-
lecular and Cellular Proteomics. 2014, 13 (11): 3049–3062. doi: 10.1074/mcp.M114.040196 PMID:
25044020
18. Dentin R, Liu Y, Koo SH, Hedrick S, Vargas T, Heredia J, et al. Insulin modulates gluconeogenesis by
inhibition of the coactivator TORC2. Nature. 2007, 449(7160): 366–369. PMID: 17805301
19. Ahmed SM, Daulat AM, Angers S. Tandem affinity purification and identification of heterotrimeric g pro-
tein-associated proteins. Methods Mol Biol. 2011, 756: 357–370. doi: 10.1007/978-1-61779-160-4_22
PMID: 21870239
20. Dai FF, Zhang Y, Kang Y, Wang Q, Gaisano HY, Braunewell KH, et al. The neuronal Ca2+ sensor pro-
tein visinin-like protein-1 is expressed in pancreatic islets and regulates insulin secretion. J Biol Chem.
2006, 281(31): 21942–21953. PMID: 16731532
21. Huang X, Dai FF, Gaisano G, Giglou K, Han J, Zhang M, et al. The identification of novel proteins that
interact with the GLP-1 receptor and restrain its activity. Mol Endocrinol. 2013, 27(9): 1550–1563 doi:
10.1210/me.2013-1047 PMID: 23864651
22. Hardy AB, Fox JE, Giglou PR, Wijesekara N, Bhattacharjee A, Sultan S, et al. Characterization of Erg K
+ channels in alpha- and beta-cells of mouse and human islets. J Biol Chem. 2009, 284(44): 30441–
30452. doi: 10.1074/jbc.M109.040659 PMID: 19690348
23. Xiao Q, JengW, Wheeler MB. Characterization of glucagon-like peptide-1 receptor-binding determi-
nants. J Mol Endocrinol. 2000, 25(3), 321–335. PMID: 11116211
24. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environ-
ment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13(11): 2498–
2504.23. PMID: 14597658
25. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, BirnbaumMJ. Biguanides suppress hepatic glucagon sig-
nalling by decreasing production of cyclic AMP. Nature. 2013, 494 (7436): 256–260 doi: 10.1038/
nature11808 PMID: 23292513
26. Syme CA, Zhang L, Bisello A. Caveolin-1 regulates cellular trafficking and function of the glucagon-like
peptide 1 receptor. Molecular Endocrinology. 2006, 20(12), 3400–3411. PMID: 16931572
27. Ke J, Zhang C, Harikumar KG, Zylstra-Diegel CR, Wang L, Mowry LE, et al. Modulation of beta-catenin
signaling by glucagon receptor activation. PLoS One. 2012, 7(3): e33676. doi: 10.1371/journal.pone.
0033676 PMID: 22438981
28. Yabaluri N, BashyamMD. Hormonal regulation of gluconeogenic gene transcription in the liver. J
Biosci. 2010, 35(3): 473–484. PMID: 20826956
29. Fu H, Subramanian RR, Masters SC. 14-3-3 proteins: structure, function, and regulation. Annual review
of pharmacology and toxicology. 2000, 40(1): 617–647.
Glucagon Receptor Interactors
PLOS ONE | DOI:10.1371/journal.pone.0129226 June 15, 2015 18 / 19
30. Siu FY, He M, de Graaf C, Han GW, Yang D, Zhang Z, et al. Structure of the human glucagon class B
G-protein-coupled receptor. Nature. 2013, 499(7459): 444–449. doi: 10.1038/nature12393 PMID:
23863937
31. Song J, Hao Y, Du Z, Wang Z, Ewing RM. Identifying novel protein complexes in cancer cells using epi-
tope-tagging of endogenous human genes and affinity-purification mass spectrometry. J Proteome
Res. 2012, 11(12): 5630–5641. doi: 10.1021/pr300598t PMID: 23106643
32. Liu H, Yuan Y, Guo H, Mitchelson K, Zhang K, Xie L, et al. Hepatitis B virus encoded X protein sup-
presses apoptosis by inhibition of the caspase-independent pathway. J Proteome Res. 2012, 11(10):
4803–4813. doi: 10.1021/pr2012297 PMID: 22871131
33. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986,
232(4746): 34–47. PMID: 3513311
34. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, et al. Overproduction of VLDL1 driv-
en by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol.
2005, 25(8): 1697–1703. PMID: 15947244
35. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Plasma low density lipoprotein transport kinetics in non-
insulin-dependent diabetes mellitus. J Clin Invest. 1983, 71(3): 655–667. PMID: 6338042
36. Streicher R, Kotzka J, Muller-Wieland D, Siemeister G, Munck M, Avci H, et al. SREBP-1 mediates acti-
vation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J Biol
Chem. 1996, 271(12): 7128–7133. PMID: 8636148
37. Sekar N, Veldhuis JD. Involvement of Sp1 and SREBP-1a in transcriptional activation of the LDL recep-
tor gene by insulin and LH in cultured porcine granulosa-luteal cells. Am J Physiol Endocrinol Metab.
2004, 287(1): e128–135. PMID: 14998783
38. Wu JH, Peppel K, Nelson CD, Lin FT, Kohout TA, Miller WE, et al. The adaptor protein beta-arrestin2
enhances endocytosis of the low density lipoprotein receptor. J Biol Chem. 2003, 278(45): 44238–
44245. PMID: 12944399
39. Tseng C, Zhang XY. Role of G Protein-Coupled Receptor Kinases in Glucose-Dependent Insulinotropic
Polypeptide Receptor Signaling 1. Endocrinology. 2000, 141(3), 947–952. PMID: 10698169
40. Kaiser C. Thinking about p24 proteins and how transport vesicles select their cargo. Proc Natl Acad Sci
U S A. 2000, 97(8): 3783–3785. PMID: 10760248
41. Majoul L, Straub M, Hell SW, Duden R, Soling HD. KDEL-cargo regulates interactions between proteins
involved in COPI vesicle traffic: measurements in living cells using FRET. Dev Cell. 2001, 1(1): 139–
153. PMID: 11703931
42. Gommel DU, Memon AR, Heiss A, Lottspeich F, Pfannstiel J, Lechner J, et al. Recruitment to Golgi
membranes of ADP-ribosylation factor 1 is mediated by the cytoplasmic domain of p23. EMBO J. 2001,
20(23): 6751–6760. PMID: 11726511
43. Contreras L, Ortiz-Zapater E, Aniento F. Sorting signals in the cytosolic tail of membrane proteins in-
volved in the interaction with plant ARF1 and coatomer. Plant J. 2004, 38(4): 685–698. PMID:
15125774
44. Stepanchick A, Breitwieser GE. The cargo receptor p24A facilitates calcium sensing receptor matura-
tion and stabilization in the early secretory pathway. Biochem Biophys Res Commun. 2010, 395(1):
136–140. doi: 10.1016/j.bbrc.2010.03.156 PMID: 20361938
45. Kim GH, Park EC, Yun SH, Hong Y, Lee DG, Shin EY, et al. Proteomic and bioinformatic analysis of
membrane proteome in type 2 diabetic mouse liver. Proteomics.2013, 13(7), 1164–1179. doi: 10.1002/
pmic.201200210 PMID: 23349036
46. Sakiyama H, Wynn RM, LeeWR, FukasawaM, Mizuguchi H, Gardner KH, et al. Regulation of nuclear
import/export of carbohydrate response element-binding protein (ChREBP): interaction of an alpha-
helix of ChREBP with the 14-3-3 proteins and regulation by phosphorylation. J Biol Chem. 2008, 283
(36): 24899–24908. doi: 10.1074/jbc.M804308200 PMID: 18606808
47. Yuan Z, Agarwal-Mawal A, Paudel HK. 14-3-3 binds to and mediates phosphorylation of microtubule-
associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J Biol
Chem. 2004, 279(25): 26105–26114. PMID: 15073173
48. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, Lin R, et al. 14-3-3 connects glycogen
synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. J
Biol Chem. 2003, 278(15): 12722–12728.E PMID: 12551948
49. L i T, Paudel HK. 14-3-3 zeta facilitates GSK3 beta-catalyzed tau phosphorylation in HEK-293 cells by
a mechanism that requires phosphorylation of GSK3beta on Ser9. Neurosci Lett. 2007, 414(3): 203–
208. PMID: 17317006
50. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled
receptors and neuronal functions. Annu. Rev. Neurosci. 2004, 27: 107–144. PMID: 15217328
Glucagon Receptor Interactors
PLOS ONE | DOI:10.1371/journal.pone.0129226 June 15, 2015 19 / 19
